Compare Incyte Corporation (INCY) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs VNET Group Inc — how do they compare? Incyte Corporation trades at $117 (market cap $23.11B), while VNET Group Inc trades at $7.7 (market cap $2.19B). The key difference: Incyte Corporation is far larger — about 10.6× VNET Group Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| INCY | VNET | |
|---|---|---|
Market Cap | $23.11B | $2.19B |
Sector | Health | Technology |
52-Week High | $118.52 | $14.03 |
52-Week Low | $67.38 | $7.34 |
Enterprise Value | $19.13B | $5.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
VNET trades at $7.675, up 3.86% today, but faces bearish technical signals with 15 sell indicators against 0 buys. The company reported a Q1 2026 net loss of $1.20 per share, missing estimates, while revenue reached $390.13 million. Despite negative profitability margins, analyst consensus remains 62.5% buy-rated, citing strategic investor entry and AI-driven data center demand as growth catalysts.
The outlook hinges on execution of its data center capacity pipeline to reverse losses. Risks include persistent negative earnings, high debt, and competitive pressures. Institutional sentiment is cautiously optimistic given the 54% average price target upside, but profitability improvement is critical for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
